Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Cryptic in vitro ubiquitin ligase activity of HDMX towards p53 is probably regulated by an induced fit mechanism

KG. Calderon-González, I. Medina-Medina, L. Haronikova, L. Hernychova, O. Bonczek, L. Uhrik, V. Hrabal, B. Vojtesek, R. Fahraeus, J. Hernández-Monge, V. Olivares-Illana

. 2022 ; 42 (7) : . [pub] 20220729

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc22025132

HDMX and its homologue HDM2 are two essential proteins for the cell; after genotoxic stress, both are phosphorylated near to their RING domain, specifically at serine 403 and 395, respectively. Once phosphorylated, both can bind the p53 mRNA and enhance its translation; however, both recognize p53 protein and provoke its degradation under normal conditions. HDM2 has been well-recognized as an E3 ubiquitin ligase, whereas it has been reported that even with the high similarity between the RING domains of the two homologs, HDMX does not have the E3 ligase activity. Despite this, HDMX is needed for the proper p53 poly-ubiquitination. Phosphorylation at serine 395 changes the conformation of HDM2, helping to explain the switch in its activity, but no information on HDMX has been published. Here, we study the conformation of HDMX and its phospho-mimetic mutant S403D, investigate its E3 ligase activity and dissect its binding with p53. We show that phospho-mutation does not change the conformation of the protein, but HDMX is indeed an E3 ubiquitin ligase in vitro; however, in vivo, no activity was found. We speculated that HDMX is regulated by induced fit, being able to switch activity accordingly to the specific partner as p53 protein, p53 mRNA or HDM2. Our results aim to contribute to the elucidation of the contribution of the HDMX to p53 regulation.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22025132
003      
CZ-PrNML
005      
20250109080402.0
007      
ta
008      
221017s2022 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1042/BSR20220186 $2 doi
035    __
$a (PubMed)35674210
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Calderon-González, Karla Gisel $u Laboratorio de Interacciones Biomoleculares y cáncer. Instituto de Física Universidad Autónoma de San Luis Potosí, Av. Parque Chapultepec 1570, Privadas del pedregal, 78210, SLP, México
245    10
$a Cryptic in vitro ubiquitin ligase activity of HDMX towards p53 is probably regulated by an induced fit mechanism / $c KG. Calderon-González, I. Medina-Medina, L. Haronikova, L. Hernychova, O. Bonczek, L. Uhrik, V. Hrabal, B. Vojtesek, R. Fahraeus, J. Hernández-Monge, V. Olivares-Illana
520    9_
$a HDMX and its homologue HDM2 are two essential proteins for the cell; after genotoxic stress, both are phosphorylated near to their RING domain, specifically at serine 403 and 395, respectively. Once phosphorylated, both can bind the p53 mRNA and enhance its translation; however, both recognize p53 protein and provoke its degradation under normal conditions. HDM2 has been well-recognized as an E3 ubiquitin ligase, whereas it has been reported that even with the high similarity between the RING domains of the two homologs, HDMX does not have the E3 ligase activity. Despite this, HDMX is needed for the proper p53 poly-ubiquitination. Phosphorylation at serine 395 changes the conformation of HDM2, helping to explain the switch in its activity, but no information on HDMX has been published. Here, we study the conformation of HDMX and its phospho-mimetic mutant S403D, investigate its E3 ligase activity and dissect its binding with p53. We show that phospho-mutation does not change the conformation of the protein, but HDMX is indeed an E3 ubiquitin ligase in vitro; however, in vivo, no activity was found. We speculated that HDMX is regulated by induced fit, being able to switch activity accordingly to the specific partner as p53 protein, p53 mRNA or HDM2. Our results aim to contribute to the elucidation of the contribution of the HDMX to p53 regulation.
650    _2
$a proteiny buněčného cyklu $x metabolismus $7 D018797
650    _2
$a jaderné proteiny $x genetika $7 D009687
650    _2
$a vazba proteinů $7 D011485
650    _2
$a protoonkogenní proteiny $x genetika $7 D011518
650    12
$a protoonkogenní proteiny c-mdm2 $x genetika $x metabolismus $7 D051736
650    _2
$a messenger RNA $x metabolismus $7 D012333
650    _2
$a serin $x metabolismus $7 D012694
650    12
$a nádorový supresorový protein p53 $x genetika $x metabolismus $7 D016159
650    _2
$a ubikvitin $x genetika $7 D025801
650    _2
$a ubikvitinligasy $x genetika $x metabolismus $7 D044767
650    _2
$a ubikvitinace $7 D054875
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Medina-Medina, Ixaura $u Laboratorio de Interacciones Biomoleculares y cáncer. Instituto de Física Universidad Autónoma de San Luis Potosí, Av. Parque Chapultepec 1570, Privadas del pedregal, 78210, SLP, México
700    1_
$a Haronikova, Lucia $u Regional Centre for Applied Molecular Oncology, Masaryk Memorial Cancer Institute, Zluty kopec 7, 656 53 Brno, Czech Republic
700    1_
$a Hernychova, Lenka $u Regional Centre for Applied Molecular Oncology, Masaryk Memorial Cancer Institute, Zluty kopec 7, 656 53 Brno, Czech Republic
700    1_
$a Bonczek, Ondřej, $d 1986- $u Regional Centre for Applied Molecular Oncology, Masaryk Memorial Cancer Institute, Zluty kopec 7, 656 53 Brno, Czech Republic $7 xx0327493
700    1_
$a Uhrik, Lukas $u Regional Centre for Applied Molecular Oncology, Masaryk Memorial Cancer Institute, Zluty kopec 7, 656 53 Brno, Czech Republic
700    1_
$a Hrabal, Vaclav $u Regional Centre for Applied Molecular Oncology, Masaryk Memorial Cancer Institute, Zluty kopec 7, 656 53 Brno, Czech Republic
700    1_
$a Vojtesek, Borivoj $u Regional Centre for Applied Molecular Oncology, Masaryk Memorial Cancer Institute, Zluty kopec 7, 656 53 Brno, Czech Republic
700    1_
$a Fahraeus, Robin $u Regional Centre for Applied Molecular Oncology, Masaryk Memorial Cancer Institute, Zluty kopec 7, 656 53 Brno, Czech Republic $u Department of Medical Biosciences, Umeå University, SE-90185 Umeå, Sweden $u Équipe Labellisée Ligue Contre le Cancer, Université Paris 7, INSERM UMR 1162, 27 Rue Juliette Dodu, 75010 Paris, France
700    1_
$a Hernández-Monge, Jesús $u Catedra CONACyT- Laboratorio de Biomarcadores Moleculares. Instituto de Física, Universidad Autónoma de San Luis Potosí, México City, México
700    1_
$a Olivares-Illana, Vanesa $u Laboratorio de Interacciones Biomoleculares y cáncer. Instituto de Física Universidad Autónoma de San Luis Potosí, Av. Parque Chapultepec 1570, Privadas del pedregal, 78210, SLP, México $1 https://orcid.org/0000000169495986
773    0_
$w MED00000783 $t Bioscience reports $x 1573-4935 $g Roč. 42, č. 7 (2022)
856    41
$u https://pubmed.ncbi.nlm.nih.gov/35674210 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20221017 $b ABA008
991    __
$a 20250109080356 $b ABA008
999    __
$a ok $b bmc $g 1854703 $s 1176422
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2022 $b 42 $c 7 $e 20220729 $i 1573-4935 $m Bioscience reports $n Biosci Rep $x MED00000783
LZP    __
$a Pubmed-20221017

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...